New once-a-month injectable contraceptives, with particular reference to Cyclofem®/Cyclo-Provera®

International Journal of Gynecology and Obstetrics

Volumn 62, Issue SUPPL. 1, 1998, Pages

  Hall, P E ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Clinical trials; Contraception; Injectable; Once a month

Indexed keywords

ESTRADIOL CIPIONATE; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL VALERATE PLUS NORETHISTERONE ENANTATE; ESTROGEN; GESTAGEN; LIPID; MEDROXYPROGESTERONE ACETATE;

BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONTRACEPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG SAFETY; FEMALE; FERTILITY; HEMOSTASIS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAUTERINE CONTRACEPTIVE DEVICE; LIPID METABOLISM; MENSTRUAL CYCLE; NONHUMAN; PHASE 3 CLINICAL TRIAL; PREGNANCY RATE; PRIORITY JOURNAL;

EID: 0031691596     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(98)00090-3     Document Type: Conference Paper

References (36)

1. World Health Organization. Facts about injectable contraceptives: memorandum from a WHO meeting. Bull WHO 1982;60:210.
2. Benagiano G. Long acting systemic contraceptives in regulation of human fertility. In: Diczfalusy E, editor. Regulation of human fertility. Copenhagen: Scriptor, 1977:323-360.
3. Toppozada M. The clinical use of monthly injectable contraceptive preparations. Obstet Gynecol Surv 1977;32:335-347.
4. Hall PE, Fraser IS. Monthly injectable contraceptives. In: Mishell DR, editor. Long acting steroid contraception. New York: Raven Press, 1983;65-88.
5. Hall PE. Once-a-month injectable contraceptives. IPPF Med Bull 1987;21:1-2.
6. Liskin L, Blackburn R. Hormonal contraception: new long acting methods. The Johns Hopkins University.. Popul Rep 1987;15:K57-K87.
7. Siegel I. Conception control by long-acting progestogens. Preliminary report. Obstet Gynecol 1963; 21:666-668.
8. World Health Organization. Facts about once-a-month injectable contraceptives: memorandum from a WHO meeting. Bull WHO 1994;70:677-689.
9. Coutinho EM, de Souza JC. Conception control by monthly injections of medroxyprogesterone suspension and a long-acting oestrogen. J Reprod Fertil 1968;15:209-214.
10. Oriowo MA, Landgren B-M, Stenström B, Diczfalusy E. A comparison of the pharmacokinetic properties of three estradiol esters. Contraception 1980;21:415-424.
11. Sang G-W. Pharmacodynamic effects of once-a-month combined injectable contraceptives. Contraception 1994;49:361-385.
12. Jordan A. FDA requirements for non-clinical testing of contraceptive steroids. Contraception 1992;46:499-509.
13. Cookson KM. The parenteral toxicity of MPA/E2C. Contraception 1994;49:335-345.
14. Seibert B, Günzel P. Animal toxicity studies performed for risk assessment of the once-a-month injectable contraceptive NET-EN/EV. Contraception 1994;49:303-333.
15. Fotherby K, Benagiano G, Toppozada HK, Abdel-Rahman A, Navaroli F, Arce B et al. A preliminary pharmacological trial of the monthly injectable contraceptive Cycloprovera. Contraception 1982;25:261-272.
16. Aedo A-R, Landgren B-M, Johannisson E, Diczfalusy E. Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. Contraception 1985;31:453-469.
17. World Health Organization. Task force on long-acting systemic agents for fertility regulation, special programme of research, development and research training in human reproduction. A multicentred pharmacokinetic, pharmacodynamic study of once-a-month injectable contraceptives: I. Different doses of HRP112 and of Depoprovera. Contraception 1987;36:441-457.
18. Garza-Flores J. Pharmacokinetics of once-a-month injectable contraceptives. Contraception 1994;49:347-359.
19. Bassol S, Garza-Flores J. Return of ovulation upon discontinuation of once-a-month injectable contraceptives. Contraception 1994;49:441-453.
20. Bahamondes L, Lavin P, Ojeda G, Petta C, Diaz J, Maradiegue E et al. Return of fertility after discontinuation of the once-a-month injectable contraceptive cyclofem. Contraception 1997;55:307-310.
21. Zinaman MJ, Clegg ED, Brown CC, O'Conner J, Selevan SG. Estimates of human fertility and pregnancy loss. Fertil Steril 1996;65:503-509.
22. World Health Organization. Task force on long-acting systemic agents for fertility regulation. A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection: I. Contraceptive efficacy and side-effects. Contraception 1988;37:1-20.
23. Sang GW, Shao QX, Ge RS, Ge JL, Chen JK, Song S et al. A multicentred phase III comparative clinical trial of NET-EN/EV, MPA/E2C and Injectable No. 1 given monthly by intramuscular injection to Chinese women. I. Contraceptive efficacy and side effects. Contraception 1995;51:167-183.
24. Cuong DT, My Hyong NT. Comparative phase III clinical trial of two injectable contraceptive preparations, depot medroxyprogesterone acetate and MPA/E2C, in Vietnamese women. Contraception 1996;54:169-179.
25. World Health Organization. Task force on long-acting systemic agents for fertility regulation. Multinational comparative clinical trial of long-acting injectable contraceptives: norethisterone enanthate given in two dosage regimens and depot medroxyprogesterone acetate. Contraception 1983;28:1-20.
26. World Health Organization. Task force on long-acting systemic agents for fertility regulation. A multicentred phase III comparative clinical trial of depot medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 m: I. contraceptive efficacy and side-effects. Contraception 1986;34:223-235.
27. Belsey EM, Pinol APY. Task force on long-acting systemic agents for fertility regulation. Menstrual patterns in untreated women. Contraception 1997;55:57-65.
28. Sang GW, Shao QX, Ge RS, Ge JL, Chen M, Song S et al. A multicentred phase III comparative clinical trial of NET-EN/EV, cyclofem and injectable No. 1 given monthly by intramuscular injection to Chinese women. II. The comparison of bleeding patterns. Contraception 1995;51:185-192.
29. World Health Organization, Task force on long-acting systemic agents for fertility regulation. A comparative study of the effects of two once-a-month injectable steroidal contraceptives and a combined oral contraceptive on haemostasis. Contraception 1998 (in press).
30. Haiba NA, El Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE. Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters. Contraception 1989; 39:619-632.
31. World Health Organization, Task force on long-acting systemic agents for fertility regulation. A comparative study of the effects of two once-a-month injectable steroidal contraceptives (NET-EN/EV® and MPA/E2C®) on lipid and lipoprotein metabolism. Contraception 1997;56:193-207.
32. Hall PE. WHO. The introduction of MPA/E2C in National family planning programmes: experience from studies in Indonesia, Jamaica, Mexico, Thailand and Tunisia. Contraception 1994;49:489-507.
33. Hall PE, Bahamondes L, Diaz J, Petta C, Marchi NM, Nakagava H et al. Introductory studies of the once-a-month injectable contraceptive MPA/E2C in Brazil, Chile, Colombia and Peru. Contraception 1997;56:353-359.
34. World Health Organization. Improving quality of care in reproductive health: medical eligibility criteria for family planning methods. Geneva: WHO, 1996.
35. Bahamondes L, Marchi NM, Cristofoletti ML, Nakagava HM, Pellini E, Araujo F et al. Uniject as a delivery system for the once-a-month injectable contraceptive cyclofem in Brazil. Contraception 1996;53:115-119.
36. Bahamondes L, Marchi NM, Nakagava HM, de Melo MRL, Cristofoletti ML, Pellini E et al. Self-administration with Uniject of the once-a-month injectable contraceptive cyclofem. Contraception 1997;56:301-304.